

Transcatheter InterAtrial shunt device for the treatment of heart failure: Rationale and Design of the Pivotal Randomized Trial to REDUCE elevated left atrial pressure in patients with heart failure II (REDUCE LAP-HF II)

Natalia Berry, Laura Mauri, Ted Feldman, Jan Komtebedde, Dirk J. van Veldhuisen, Scott D. Solomon, Joseph M. Massaro, Sanjiv J. Shah



PII: S0002-8703(19)30297-2

DOI: <https://doi.org/10.1016/j.ahj.2019.10.015>

Reference: YMHJ 6006

To appear in: *American Heart Journal*

Received date: 3 July 2018

Accepted date: 23 October 2019

Please cite this article as: N. Berry, L. Mauri, T. Feldman, et al., Transcatheter InterAtrial shunt device for the treatment of heart failure: Rationale and Design of the Pivotal Randomized Trial to REDUCE elevated left atrial pressure in patients with heart failure II (REDUCE LAP-HF II), *American Heart Journal*(2019), <https://doi.org/10.1016/j.ahj.2019.10.015>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Pivotal Randomized Trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II)

Natalia Berry, MD;¹ Laura Mauri, MD, MSc;¹ Ted Feldman, MD;² Jan Komtebedde, DVM;³
Dirk J. van Veldhuisen, MD, PhD;⁴ Scott D. Solomon, MD;¹
Joseph M. Massaro, PhD;⁵ Sanjiv J. Shah, MD⁶

Author affiliations:

1. Brigham and Women's Hospital, Boston, MA
2. NorthShore University Health System, Evanston, IL
3. Corvia Medical, Tewksbury, MA
4. University of Groningen, Groningen, Netherlands
5. Boston University, Boston, MA
6. Northwestern University Feinberg School of Medicine, Chicago, IL

Short title: Rationale and Design of REDUCE LAP-HF II

Clinical Trial Registration: NCT03088033

Tables: 2

Figures: 2

Disclosures:

NB: none

LM: grants from Amgen, Abbott, Boston Scientific, Boehringer Ingelheim, Biotronik, Corvia, during the conduct of the study; personal fees from Amgen, Eli Lilly, St. Jude Medical, Recor, Corvia, and Biotronik; and honoraria from Daiichi Sankyo, Astra Zeneca, Sanofi, outside the submitted work. LM is currently employed by Medtronic, Inc.

TF: grants and consulting fees from Abbott, BSC, Edwards, Gore. TF is currently employed by Edwards Medical, Inc.

JK: employee of and stock options in Corvia Medical

DJV: none

SDS: consultant for Corvia Medical

JMM: paid statistical consultant for Corvia Medical

SJS: grants from Actelion, AstraZeneca, Corvia, and Novartis; and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ironwood, Merck, Novartis, Sanofi, Tenax, and United Therapeutics

Address for correspondence:

Sanjiv J. Shah, MD

Division of Cardiology, Department of Medicine

Northwestern University Feinberg School of Medicine

676 N. St. Clair St., Suite 600

Chicago, IL 60611

Email: sanjiv.shah@northwestern.edu

ABSTRACT

Background: A randomized, sham-controlled trial in patients with heart failure (HF) and left ventricular ejection fraction (LVEF) $\geq 40\%$ demonstrated reductions in pulmonary capillary wedge pressure (PCWP) with a novel transcatheter InterAtrial Shunt Device (IASD). Whether this hemodynamic effect will translate to an improvement in cardiovascular outcomes and symptoms requires additional study.

Study Design and Objectives: REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP HF-II) is a multicenter, prospective, randomized, sham-controlled, blinded trial designed to evaluate the clinical efficacy of the IASD in symptomatic HF and elevated left atrial (LA) pressures. Up to 608 HF patients age ≥ 40 years with LVEF $\geq 40\%$, PCWP ≥ 25 mmHg during supine ergometer exercise, and PCWP ≥ 5 mmHg higher than right atrial pressure will be randomized 1:1 to the IASD versus sham control. Key exclusion criteria include hemodynamically significant valvular disease, evidence of pulmonary arterial hypertension, and right heart dysfunction. The primary endpoint is a hierarchical composite of (1) cardiovascular mortality or first non-fatal ischemic stroke; (2) HF hospitalizations or healthcare facility visits for intravenous diuresis; and (3) change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, all at 12 months, analyzed by Finkelstein-Schoenfeld methodology. Follow-up echocardiography will be performed at 6, 12, and 24 months to evaluate shunt flow and cardiac chamber size/function. Patients will be followed for a total of 5 years after the index procedure.

Conclusions: REDUCE LAP-HF II is designed to evaluate the clinical efficacy of the IASD device in patients with symptomatic HF with elevated LA pressure and LVEF $\geq 40\%$.

Key words: heart failure; randomized controlled trial; shunt; treatment

Background

Heart failure (HF) has a prevalence of over 26 million people worldwide,¹ and carries with it significant morbidity and mortality.^{2,3} An estimated \$30.7 billion dollars is spent annually in the US on HF.² More than one half of patients with HF have preserved ejection fraction (HFpEF; EF > 50%), and this proportion has increased over time.^{4,5} HF with mid-range EF (HFmrEF; EF 40-50%) is increasingly recognized as an understudied and important subgroup of HF patients that shares characteristics with both HFpEF and HF with reduced EF (HFrEF).

Although a multitude of pharmacologic therapies exist which have been shown to improve mortality and reduce symptoms in patients with HFrEF, there are no such therapies that have been shown to improve outcomes in patient with preserved or mid-range EF.⁵⁻⁷ Therapy consists of treatment of volume overload with diuretics when present and management of coexisting medical conditions with the goal of improving exercise tolerance and quality of life, and preventing hospitalization.⁵ Thus, in patients with HF and EF > 40%, there is a pressing unmet need for novel therapeutics.

Although HFpEF is now considered to be a systemic syndrome that is more complex than simply a disease of left ventricular (LV) hypertrophy and LV diastolic dysfunction, elevated left atrial (LA) pressure is still the primary hemodynamic cardiac abnormality in patients with HFpEF.^{4,8} Elevated LA pressure is transmitted to the pulmonary capillary bed, especially during exercise,⁹⁻¹² and contributes to symptoms of shortness of breath, fatigue, fluid retention, and mortality.¹³⁻¹⁵ Thus, treatment of elevated LA pressure, particularly during exertion, could improve symptoms and outcomes in HFpEF, and may do the same for HFmrEF.

Historical experience with mitral stenosis, a condition associated with elevated LA related to obstructed outflow, showed that patients with co-existing atrial septal defects

(Lutembacher syndrome, first described in 1916)¹⁶ had fewer symptoms and better outcomes than patients with isolated mitral stenosis.^{17, 18} Hemodynamic computer modeling has suggested that creation of an interatrial shunt could effectively mitigate increases in LA pressure in patients with HFpEF.¹⁹ This led to postulation that controlled creation of a left-to-right interatrial shunt might be a therapeutic intervention, and provided the rationale for the development of a novel InterAtrial Shunt Device (IASD, Corvia Medical Inc. Tewksbury, USA) for the treatment of HF.

This IASD has been evaluated in patients with HF and EF > 40% in 3 separate previous trials. A pilot, open-label, single-arm evaluation of the Corvia IASD in n=11 patients with EF ≥ 45% demonstrated a decrease in pulmonary capillary wedge pressure (PCWP) at 30 days with improvement in symptoms, NYHA class, and quality of life compared with baseline at 1 year.^{20,}

21

The REDUCE Left Atrial Pressure in Heart Failure (REDUCE LAP-HF) trial was an open-label, single-arm trial which evaluated the performance and safety of the Corvia IASD in 68 patients (n=64 received the IASD implant) all of whom had LVEF ≥ 40%. In this trial, there were no peri-procedural or major adverse cardiac or cerebrovascular event through 6 months of follow-up, and 58% of patients had a lower PCWP during exertion at 6 months.^{22, 23} At 12 months there were sustained improvements in hemodynamics, NYHA class, quality of life, and 6 minute walk test distance.²⁴ The device has remained patent in all patients in follow-up to date. While the results of the REDUCE LAP-HF open-label trial were promising from both a therapeutic and safety standpoint, the non-randomized, non-blinded nature of the trial limited the ability to make causal inferences about the efficacy of the device. Thus, additional properly controlled trials were required to further evaluate the hemodynamic and clinical effectiveness of the device.

The REDUCE LAP-HF I trial was a phase 2, prospective, randomized, blinded, sham-controlled clinical trial that included 44 patients with LVEF $\geq 40\%$ (and no previously documented EF $<30\%$ within 5 years prior to enrollment). Right heart catheterization was used for both baseline and 1-month follow-up assessment of PCWP. Patients were randomized 1:1 to the IASD or sham control procedure. There was a greater reduction in exercise PCWP at 1 month in the IASD group compared with control without any peri-procedural or major adverse cardiac, cerebrovascular, or renal events in the IASD group.^{25, 26} Importantly, protocol-driven echocardiographic follow-up has not identified right-sided HF or pulmonary hypertension associated with the IASD, and the device has remained patent in all patients in follow-up to date. The REDUCE LAP-HF I trial was important because it showed the hemodynamic effectiveness of the device, thereby obviating the need for cumbersome repeated invasive hemodynamic testing in future studies, setting the stage for a larger-scale pivotal trial to determine the clinical effectiveness of the IASD. One year safety and clinical outcomes of the REDUCE LAP-HF I trial, which have now been published, show that the device remains patent at 1 year in all patients, and appears to be safe. In addition, there were non-significant trends towards reduced HF hospitalizations in the patients randomized to the IASD.²⁷

Here we describe the investigational device, study design, inclusion/exclusion criteria, key endpoints, and statistical analysis for the REDUCE Elevated Left Atrial Pressure in patients with Heart Failure II (REDUCE LAP-HF II, ClinicalTrials.gov NCT03088033) trial, a multicenter, prospective, randomized controlled, blinded trial with a non-implant sham procedure control group to evaluate the clinical efficacy of the IASD for patients with HF and preserved or mid-range LV ejection fraction.

Methods

Device Description

The IASD System II Implant (Corvia Medical, Tewksbury, MA) consists of a one-piece self-expanding nitinol cage with a double-disc design with an opening (barrel) in the center (Figure 1). The implant is radiopaque and echogenic to allow for imaging during the implantation procedure. It is designed to have the necessary structural integrity to maintain device shape and function for long-term use. Each side of the implant is multi-legged (9 legs/side), and the LA disk has a radiopaque marker at the end of each leg. The LA side of the implant is flat to allow the legs to rest flush against the LA wall, thereby minimizing the LA profile of the implant. The right atrial side is curved to accommodate variable septal wall thicknesses. The expanded external diameter of each disk is 19.4 mm, and the inner diameter of the barrel in the center of the fully expanded implant is 8 mm.

The delivery system is designed to deploy the implant at the target location across the interatrial septum. The system consists of a delivery catheter with an integrated handle and preloaded implant, with an over the wire design that is 0.035" guide wire compatible. The implant comes preloaded in a collapsed configuration onto the distal tip of the inner catheter of the delivery system. Implant deployment is achieved by retracting the outer sheath to release the implant legs and barrel in a controlled stepwise manner on the left and the right atrial septal surfaces. The handle has a thumb slide that is used to advance or retract the outer sheath, and is designed with safety features designed to prevent accidental deployment.

Objective and Overview of Study Design

The primary objective of the REDUCE LAP HF II Study is to evaluate the clinical efficacy and safety of the IASD system in symptomatic heart failure patients with an LV ejection fraction $\geq 40\%$, and elevated left sided filling pressures despite standard guideline-directed medical therapy (GDMT).

This study is a multicenter, prospective, randomized controlled, blinded trial with a non-implant sham control procedure group, and 1:1 randomization. Patients will be followed for 1 year, and annually every 12-months thereafter, for a total of 5 years after index procedure and implant.

Study Population

The full list of inclusion and exclusion criteria are listed in Table 1. Patients age ≥ 40 years with NYHA class II or III chronic symptomatic HF with LV ejection fraction $\geq 40\%$, with ongoing diuretic therapy, and with elevated left sided filling pressures defined as PCWP ≥ 25 mmHg during supine ergometer exercise, and PCWP greater than right atrial pressure (RAP) by ≥ 5 mmHg, with echocardiographic evidence of diastolic dysfunction, who are candidates for transseptal catheterization, are eligible for enrollment.

Exclusion criteria include recent myocardial infarction, revascularization, recent stroke, advanced heart failure (NYHA class IV, inotrope therapy, cardiac index <2.0 L/min, transplant listed), hemodynamically significant valvular disease or cardiomyopathy, existing atrial septal defect (ASD), uncontrolled atrial fibrillation (HR >100 bpm), known right ventricular (RV) dysfunction or pulmonary vascular resistance >3.5 Wood units.

Patients will be enrolled from up to 100 sites in the United States, Australia, Austria, Belgium, Canada, Croatia, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, and the United Kingdom.

Randomization

All enrolled patients who are eligible based on non-invasive evaluation will undergo pre-randomization resting and exercise right heart catheterization. Eligible patients who qualify based on invasive hemodynamic criteria will be randomized in a 1:1 fashion within the Electronic Data Capture (EDC) system to receive the IASD or sham-control procedure (see patient flow chart, Figure 2). Randomization will be stratified by geography (United States vs. Outside United States), age (age <75 and ≥ 75), and gender to ensure balanced groups on these factors.

After hemodynamic qualification, all patients will be sedated, and will undergo intra-cardiac echocardiography or transesophageal echocardiography to ensure no previously undetected exclusions are present (including ASD, LA thrombus, or severe septal aneurysm and thickening).

After randomization, both treatment and control arm patients will undergo placement of a femoral venous access sheath. Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography or transesophageal echocardiography guided trans-septal puncture and IASD System II implant procedure. Patients randomized to the control arm will undergo fluoroscopy and intra-cardiac echocardiography from the femoral vein or transesophageal echocardiography for examination of the atrial septum and LA appendage

(the sham control procedure consisting of placement of the femoral venous access sheath and the echocardiographic exam).

Patient blinding will include sedation, earphones with music to prevent the patient from hearing the procedure discussions, and shielding of the patients to prevent viewing the imaging screens during the procedure. The patients, the physicians managing the randomized patients, research individuals involved in conducting selected post randomization evaluations, and the hemodynamic, echocardiographic and cardiopulmonary exercise test (CPET) core laboratories (The Center for Quantitative Echocardiography, Hospital of University of Pennsylvania for Echocardiography; Wake Forest University for CPET), will be blinded to study arm.

Patients will be followed for one year (at 2-weeks and 1, 3, 6 and 12 months post-procedure), and annually every 12 months thereafter for a total of 5 years after the index procedure and implant. All patients will be unblinded after the 24-month follow-up visit. Patients randomized to the control arm will be allowed to cross over to the treatment arm within 45 days of the 24-month visit, provided patient inclusion/exclusion criteria are met at that time. Cross-over patients will then be followed for 5 years after cross-over.

Endpoints

The primary endpoint is the composite of (a) incidence of and time-to-cardiovascular mortality or first non-fatal, ischemic stroke through 12 months; (b) rate (first plus recurrent) of HF admissions or healthcare facility visits for intravenous diuresis for HF through 12 months including time-to-first HF event; and (c) change in baseline KCCQ total summary score at 12 months. Treatment groups will be compared with respect to the distribution of these components using the Finkelstein-Schoenfeld approach as detailed in the next section²⁸

The major secondary endpoints are the change in NYHA class and in KCCQ from baseline to 12 months. Other secondary outcome measures are described in Table 2.

Statistical Considerations

The primary endpoint will be compared between treatments using the Finkelstein-Schoenfeld (F-S)²⁷ approach, a non-parametric method that allows for prioritization of more clinically important components when comparing two treatments on a composite endpoint. The null and alternative hypotheses are: $H_0: T=0$ vs $H_1: T \neq 0$ where T is the true value of the Finkelstein-Schoenfeld (F-S) statistic²⁸. The hierarchy in the estimation of the F-S statistic T is CV mortality/non-fatal ischemic stroke component, followed by the HF event component, followed by the KCCQ component. Specifically, the F-S statistic T is estimated from the clinical trial sample as follows: The first patient is compared to every patient, one at a time, and this first patient is assigned a score of 1/0/-1 for *each* comparison if this first patient has a better (did not experience CV death/ischemic stroke and the comparator patient did), same, or worse (experienced CV death/ischemic stroke and the comparator patient did not) outcome, respectively. For every pairwise comparison where the score is 0, the first patient is assigned a score of 1/0/-1 depending on whether he/she has a better (less HF events than the comparator patient), same (same number of HF events as the comparator patient), or worse outcome (more HF events than the comparator patient), respectively. Finally, for every pairwise comparison where the score is still 0, the first patient is assigned a score of 1/0/-1 depending on whether he/she has a better (change in 12-month KCCQ score at least 5 points larger than the comparator), same (change in 12-month KCCQ score within +/-5 points of comparator) or worse (change in 12-month KCCQ 5 at least 5 points lower than the comparator). This algorithm is

then repeated for every patient in the study. The F-S T value is the sum of the 1/0/-1 scores across all patients in the IASD group. A T-score significantly larger than 0 indicates the IASD group has a more favorable distribution of components than the control group. The null hypothesis will be tested at a two-sided 0.05 level of significance.

In order to determine sample size to provide adequate power, the following assumptions were made for the components; they were based on data from the REDUCE LAP-HF 1 study: (a) The combined CV mortality, non-fatal ischemic stroke rate is 5.0% in each treatment group at 12 months; (b) The per person-year rate of HF events is 0.5 in control and 0.39 in IASD; for patients experiencing HF, the median time to first HF admission is 84 days in control and 172 days in IASD; (c) The mean improvement in KCCQ is assumed to be 13 in IASD and 8 in control, with a standard deviation of 20 in each treatment group; (d) Correlation between probability of death and probability of heart failure events is 0.3 or less; correlation between probability of death and improvement in KCCQ is -0.3 or larger; correlation between probability of heart failure and improvement in KCCQ is -0.3 or larger.

Under these assumptions, an evaluable sample size of 282 patients per treatment group yields 85% power to claim a significant beneficial effect of IASD over control with respect to the combined distribution of the three endpoint components at a two-sided 0.05 level of significance using the F-S approach. Power was calculated using 1000 Monte Carlo simulations carried out in SAS Version 9.4. An evaluable patient for this analysis is one who either experienced cardiovascular mortality or non-fatal ischemic stroke before the 12-month time point (and hence can be included in the analysis) or who attended the 12-month visit and completed the KCCQ at that visit. Assuming a premature withdrawal rate of no more than 7.5% prior to 12 months, then the 282 evaluable patients per treatment group leads to a requirement of 304 randomized patients

per treatment group ($304 = 282$ divided by $(1-0.075)$, where 0.075 or 7.5% is the assumed premature withdrawal rate).

In addition to the F-S p-value, two effect sizes will be presented: the (a) Win Ratio as described by Pocock et al.²⁹; and (b) the probability that the IASD patients have a more favorable distribution of the three components than control patients.

Also, as supportive analyses, appropriate descriptive statistics of each component (cumulative incidence of CV mortality/ischemic stroke where non-CV death is treated as a competing risk; person-year rate of HF events and cumulative incidence of at least one HF event) will be presented for each randomized treatment group.

Poolability

The primary analysis will combine all study centers. In order to assess poolability of primary endpoint results across study centers, assessment of treatment-by-study center interaction will be carried out for the components of the primary endpoint using Cox proportional hazards regression for 12-month cardiovascular mortality/non-fatal ischemic stroke, zero-inflated Poisson regression for 12-month HF events, and analysis of covariance adjusting for baseline KCCQ for change in KCCQ from baseline to 12 months. Treatment and study center and the treatment-by-study center interaction will be included as effects in each model. A treatment-by-study center interaction that is significant at the 0.15 level of significance will signal that the treatment difference on the component(s) may differ across study centers; a non-significant interaction, or an interaction that is significant but where IASD still yields descriptively better results than control in each center, will support the pooling of results across study centers for the final analyses. If there are too few patients in study centers such that the

models do not converge or give unstable results (e.g., estimates with very large standard errors), then treatment-*by-region* interaction will instead be assessed in a similar manner as described above, where study centers will be grouped into regions once enrollment is complete and prior to breaking the blind. Currently, the plan is to define regions as United States and Outside United States. However, this may change to more than 2 regions depending on enrollment in the various geographic areas. E.g. we may consider assigning sites to four regions such as United States, Canada, Europe, New Zealand/Australia. Again, this will be decided once enrollment is complete. The goal is to have at least 50 randomized subjects in each region.

Descriptive statistics of baseline and outcome variables to be analyzed will be presented by treatment group; such statistics include sample size, mean, median, standard deviation, and quartiles for continuous variables; counts and percent of patients for categorical variables, and Kaplan-Meier estimates of event rate for time-to-event variables. P-values will be considered significant at a two-sided 0.05 level unless otherwise specified. Analyses will be conducted using SAS Version 9.4 or higher.

Interim Analysis

After 250 of the 608 randomized patients reach 12-month follow-up or prematurely withdraw prior to 12 months post-randomization, an interim analysis on the primary endpoint will be performed using the available evaluable patients in order to assess if a sample size increase is warranted to maintain a (conditional) power of at least 80% for the study. Given the complexity of the F-S method and given that there is no closed-form equation for power or conditional power, conditional power will be assessed via Monte Carlo simulations in SAS

Version 9.4 using a method similar to that used in the overall power calculation above.

Specifically, 1,000 Monte-Carlo samples of post-interim patients will be simulated.

The size of each simulated sample is the number of patients needed post-interim to reach the required final evaluable sample size of 282 patients per group. In these simulations, the true CV mortality/ischemic stroke incidence, the true per-person-year HF event rate, and the true mean/standard deviation of change in KCCQ for each of the two treatment groups will now be assumed to be the same as the values observed in the interim dataset.

Each simulated dataset will be added to the observed (i.e., not simulated) interim analysis evaluable dataset to create 1,000 complete datasets with an evaluable sample size of 282 per group. The (simulated) conditional power is the percentage of these 1,000 simulated datasets for which the F-S test statistic is able to reject the null hypothesis. Following the methodology in Mehta and Pocock³⁰, if the conditional power is between 38% and 80%, the sample size may be increased to yield a (simulated) conditional power of 80% without paying an alpha penalty. Otherwise, the study will continue with the planned original enrollment goal of 282 evaluable patients (304 randomized) per treatment group.

Analysis populations

Analysis of the primary end point will be carried out on the intention to treat population (ITT) and the modified intention to treat (MITT) population. The ITT population is defined as all randomized patients; the MITT is defined as the ITT population excluding subjects in whom a new, previously unidentified protocol exclusion is discovered before insertion of the investigational device. The MITT population is the primary analysis population. Analyses will also be carried out on the evaluable at 12 months population (MITT patients with 12 months of

follow up available), the per-protocol population (patients who were evaluable at 12 months without major protocol violations and who (a) were randomized to IASD and had an implant; or (b) were randomized to control and underwent the complete control procedure). Safety analyses will be carried out on the safety population (subset of ITT in whom an implant of the IASD was attempted or in whom a control procedure was attempted).

Subgroup Analyses

Prospectively planned subgroup investigations include: age (<75 vs. ≥ 75), male vs. female, atrial fibrillation vs. sinus rhythm, prior year hospitalization vs. no prior year hospitalization, ejection fraction mid-range (40-50%) vs. preserved ($> 50\%$), body mass index < 30 vs. > 30 kg/m², tricuspid annular plane systolic excursion < 2 vs. > 2 cm, no tricuspid regurgitation vs. grade 1 tricuspid regurgitation, left atrial volume index (LAVI) < 34 vs. LAVI > 34 , diabetics vs. non-diabetics, region (United States vs. Outside United States). For each subgrouping, in order to assess homogeneity of treatment effect on the primary endpoint components across the subgroup categories, assessment of treatment-by-subgroup category interaction will be carried out using Cox proportional hazards regression for 12-month cardiovascular mortality/non-fatal ischemic stroke, zero-inflated Poisson regression for 12-month HF events, and analysis of covariance for change in KCCQ from baseline to 12 months. Treatment and subgroup category and the treatment-by-subgroup category interaction will be included as independent variables in each model. For KCCQ, the baseline KCCQ will also be included as a covariate. The purpose of this analysis is not to assess significance of the treatment difference on the endpoints within subgroups but to assess consistency of treatment effect on the endpoints within subgroups.

In addition, homogeneity of treatment effect on the primary endpoint components will be evaluated across the range of baseline values for each of the continuous variables listed below. Specifically, assessment of the significance of the treatment-by-baseline value interactions will be carried out for each of the variables below using Cox proportional hazards regression for the outcome 12-month cardiovascular mortality / non-fatal ischemic stroke; zero-inflated Poisson regression for 12-month HF events; analysis of covariance for change in KCCQ from baseline to 12 months. For each of the following variables (peak exercise pulmonary capillary wedge pressure [PCWP], peak exercise RA pressure, peak exercise PCWP-RA gradient, KCCQ overall summary score, 6MWT distance, and eGFR), treatment, baseline value of the variable, and the treatment-by-baseline value interaction will be included as the independent variables in each model. For the KCCQ outcome, the baseline KCCQ will also be included as a covariate.

Missing data

The primary endpoint analysis will be on the MITT population, with secondary analysis on the PP population. In the MITT analysis, patients may have missing information on cardiovascular death/non-fatal ischemic stroke, HF events, and/or on KCCQ prior to the 12-month time point, primarily due to premature withdrawal from the study. Analyses will be performed on the MITT population with available data. However, as sensitivity analyses, the primary endpoint analysis will be repeated on the entire MITT population, where missing data for the components of the primary endpoint will be multiply imputed with 50 imputations using linear regression for KCCQ and the bootstrap imputation approach for time-to-event data as outlined in Jackson et al.³¹; there will be no imputation for other endpoints in the study.

Study Administration and Management

The local Institutional Review Board or Ethics Committee at each participating institution must approve the study, and all patients must provide written informed consent prior to enrollment. Funding is provided by Corvia Medical, Inc. The Baim Institute for Clinical Research maintains the complete study database and will perform all analyses.

An independent Clinical Events Committee will adjudicate serious adverse events and outcome data. An independent Data Monitoring Safety Board monitoring safety will meet regularly to review adverse events and outcome data. A steering committee will provide strategic leadership for the study. All hemodynamic, echocardiographic, CPET, cardiac MRI, quality of life, and hemodynamic data will be adjudicated by independent core laboratories to ensure data consistency.

Funding

Funding for this study was provided by Corvia Medical. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents.

Discussion

Heart failure with preserved and mid-range ejection fraction are both associated with significant morbidity and mortality.² In patients with HFpEF, elevated LA pressure and in turn, PCWP, have been associated with increased mortality and poorer outcomes.^{14, 15, 32} We hypothesize that lowering LA pressure in patients with symptomatic HF by creating an

appropriately sized left-to-right shunt will lead to symptomatic improvement (particularly during exertion), reduced HF hospitalizations, and improved exercise tolerance and quality of life.

Additionally, a device-based therapy may avoid some of the difficulties with patient noncompliance and polypharmacy, which are often encountered in older patients with multiple comorbidities.

The REDUCE LAP-HF II study has several key design elements to reliably evaluate the safety and efficacy of the Corvia Medical Inc. IASD System II in HF patients with elevated LA pressures. It is the first study involving the IASD that is powered for determining clinical efficacy. Importantly, safety outcomes (composite cardiovascular mortality and stroke) are first in the hierarchical sequence of the primary endpoint, followed by HF hospitalizations and the KCCQ, which evaluates quality of life. Based on knowledge of the device as well as prior experience, there is no expected effect on either cardiovascular mortality or stroke at one year, however it is important to include these outcomes to further establish the safety of the IASD in a broad group of patients with HF and $EF \geq 40\%$.

The potential effect on HF admissions or healthcare facility visits for intravenous diuresis, included as the second component in the hierarchical outcome, is important both from a patient, caregiver, and resource-utilization perspective. The KCCQ endpoint is also important to quantify a clinically meaningful improvement in quality of life, and has been validated in prior studies.³³ An endpoint of 12 months will be important to allow for the sustained hemodynamic effect of the IASD on outcomes to be observed. While REDUCE LAP-HF I demonstrated positive results with short-term (1 month) post-procedural reduction in exercise PCWP and trends to fewer HF hospitalizations and greater improvement in NYHA class in patients in the

IASD group, it will be important to determine whether this translates to a clinically meaningful durable effect. Moreover, continued safety monitoring will be paramount at 12 months.

REDUCE LAP-HF I also demonstrated the mechanistic basis for the observed clinical outcomes. Direct, invasive hemodynamic assessment of exercise PCWP demonstrated that IASD results in decreased exercise PCWP.²⁶ This prior demonstration of the mechanism of the treatment effect of the IASD, reduced PCWP with exercise, will support our understanding of the clinical outcomes in REDUCE LAP-HF II. REDUCE LAP-HF I results at 12 months also demonstrate trends to fewer hospitalizations ($p=0.064$) and greater improvement in NYHA class (0.086) in patients assigned to IASD; REDUCE LAP-HF II will be important for further investigation of such trends.

The size of this trial allows exploration of variability across study centers, in the US and outside with more diverse center and patient characteristics compared to prior studies. It will also allow for more accurate detection of variations in IASD effectiveness across subgroups, specifically among males/females; patients with greater or less than BMI of 30 kg/m²; patients with higher risk features such as hospitalization within the past year; LVEF subgroups; and variations in RV function and tricuspid regurgitation at baseline. Follow up to 5 years will be important to evaluating continued device safety as well as long term effect durability.

Conclusions

The REDUCE LAP-HF II trial, the first prospective, multicenter, randomized, blinded, sham-controlled trial to evaluate clinical endpoints in patients treated with the IASD, has the potential to advance our understanding of this first-in-class, novel, transcatheter device-based therapy for HF.

Acknowledgments

The study is funded by Corvia Medical, Inc.

Journal Pre-proof

REFERENCES

1. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. *ESC Heart Fail* 2014;1(1):4-25.
2. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation* 2017;135(10):e146-e603.
3. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. *Curr Heart Fail Rep* 2013;10(4):401-10.
4. Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. *Pflugers Arch* 2014;466(6):1037-53.
5. Redfield MM. Heart Failure with Preserved Ejection Fraction. *N Engl J Med* 2016;375(19):1868-1877.
6. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! *J Am Coll Cardiol* 2010;55(6):526-37.
7. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. *Circulation* 2016;134(1):73-90.
8. Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. *J Am Coll Cardiol* 2007;49(9):972-81.
9. Maeder MT, Thompson BR, Htun N, Kaye DM. Hemodynamic determinants of the abnormal cardiopulmonary exercise response in heart failure with preserved left ventricular ejection fraction. *J Card Fail* 2012;18(9):702-10.
10. Borlaug BA. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. *Circ J* 2014;78(1):20-32.
11. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. *Circ Heart Fail* 2010;3(5):588-95.
12. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med* 2004;350(19):1953-9.
13. Carson PE, Anand IS, Win S, Rector T, Haass M, Lopez-Sendon J, et al. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). *JACC Heart Fail* 2015;3(6):429-441.
14. Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieske B, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. *Eur Heart J* 2014;35(44):3103-12.
15. Zile MR, Bennett TD, El Hajj S, Kueffer FJ, Baicu CF, Abraham WT, et al. Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. *Circ Heart Fail* 2017;10(1).
16. Lutembacher R. De la Stenose mitrale avec communication interauriculaire. *Arch Mal Coeur* 1916;9:237-260.

17. Sambhi MP, Zimmerman HA. Pathologic physiology of Lutembacher syndrome. *Am J Cardiol* 1958;2(6):681-6.
18. Rosenthal L. Atrial septal defect with mitral stenosis (Lutembacher's syndrome) in a woman of 81. *Br Med J* 1956;2(5005):1351.
19. Kaye D, Shah SJ, Borlaug BA, Gustafsson F, Komtebedde J, Kubo S, et al. Effects of an interatrial shunt on rest and exercise hemodynamics: results of a computer simulation in heart failure. *J Card Fail* 2014;20(3):212-21.
20. Sondergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. *Eur J Heart Fail* 2014;16(7):796-801.
21. Malek F, Neuzil P, Gustafsson F, Kaye DM, Walton A, Mates M, et al. Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. *Int J Cardiol* 2015;187:227-8.
22. Hasenfuss G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. *Lancet* 2016;387(10025):1298-304.
23. Hasenfuss G, Gustafsson F, Kaye D, Shah SJ, Burkhoff D, Reymond MC, et al. Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial. *J Card Fail* 2015;21(7):594-600.
24. Kaye DM, Hasenfuss G, Neuzil P, Post MC, Doughty R, Trochu JN, et al. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. *Circ Heart Fail* 2016;9(12).
25. Feldman T, Komtebedde J, Burkhoff D, Massaro J, Maurer MS, Leon MB, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). *Circ Heart Fail* 2016;9(7).
26. Feldman T, Mauri L, Kahwash R, Litwin S, Ricciardi MJ, van der Harst P, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. *Circulation* 2018;137(4):364-375.
27. Shah SJ, Feldman T, Ricciardi MJ, Kahwash R, Lilly S, Litwin S, et al. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial. *JAMA Cardiol* 2018;3(10):968-977.
28. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. *Stat Med* 1999;18(11):1341-54.
29. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. *Eur Heart J* 2012;33(2):176-82.
30. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. *Stat Med* 2011;30(28):3267-84.

31. Jackson D, White IR, Seaman S, Evans H, Baisley K, Carpenter J. Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation. *Stat Med* 2014;33(27):4681-94.
32. Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. *Circulation* 2010;121(9):1086-95.
33. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. *J Am Coll Cardiol* 2000;35(5):1245-55.

FIGURE LEGENDS

Figure 1.

Title: The Corvia InterAtrial Shunt Device

Figure 2.

Title: Study Design

Journal Pre-proof

TABLES

Table 1: Inclusion and Exclusion Criteria of the REDUCE LAP-HF II Trial

Inclusion Criteria
1. Chronic symptomatic HF documented by the following: a. Symptoms of HF requiring current treatment with diuretics for ≥ 30 days AND b. NYHA class II if a prior history of $>$ NYHA class II; OR NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening visit; or signs (any rales post cough, chest x-ray demonstrating pulmonary congestion,) within past 12 months; AND c. ≥ 1 HF hospital admission (with HF as the primary, or secondary diagnosis); or treatment with IV; or the need for intensification of oral diuresis for HF in a healthcare facility within the 12 months prior to study entry; OR an NT-pro BNP value > 150 pg./ml in normal sinus rhythm, > 450 pg./ml in atrial fibrillation, or a BNP value > 50 pg./ml in normal sinus rhythm, > 150 pg./ml in atrial fibrillation within the past 6 months.
2. Ongoing stable GDMT HF management and management of potential comorbidities according to the 2017 ACC/AHA Guidelines for the Management of HF, with no significant changes ($>100\%$ increase or 50% decrease), excluding diuretic dose changes, for a minimum of 4 weeks prior to enrollment which is expected to be maintained for 6 months. Stable management includes a minimum period of 4 weeks post hospitalization for any cause, including treatment with IV diuretics.
3. Age ≥ 40 years old
4. Site determined echocardiographic LV ejection fraction $\geq 40\%$ within the past 6 months, without documented ejection fraction $< 30\%$ in the 5 years prior to study entry.
Site determined elevated PCWP with a gradient compared to RAP documented by: a. End-expiratory PCWP during supine ergometer exercise ≥ 25mm Hg, and greater than RAP by $\geq$

5 mm Hg.
6. Site determined echocardiographic evidence of diastolic dysfunction documented by one or more of the following: a. LA diameter > 4 cm; or b. Diastolic LA volume > 50, LA volume index > 28 ml/m² or c. Lateral e' < 10 cm/s; or d. Septal e' < 8 cm/s; or e. Lateral E/e' > 10; or f. Septal E/e' > 15
7. Patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the IRB or EC
8. Patient is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams
9. Trans-septal catheterization and femoral vein access is determined to be feasible by site interventional cardiology investigator.
Exclusion Criteria
1. MI and/or percutaneous cardiac intervention within past 3 months; CABG in past 3 months, or current indication for coronary revascularization; AVR (surgical AVR or TAVR) within the past 12 months; or a planned cardiac interventions in the 3 months following enrollment.
2. Cardiac resynchronization therapy initiated within the past 6 months.
3. Advanced heart failure defined as one or more of the below: a. ACC/AHA/ESC Stage D heart failure, Non-ambulatory NYHA Class IV HF; b. Cardiac Index < 2.0 L/min/m² c. Inotropic infusion (continuous or intermittent) for EF < 40% within the past 6 months

d. Patient is on the cardiac transplant waiting list.
4. Inability to perform 6 minute walk test (distance < 50 m), OR 6 minute walk test > 600 m
5. The patient has verified that the ability to walk 6 minutes is limited primarily by joint, foot, leg, hip or back pain; unsteadiness or dizziness or lifestyle (and not by shortness of breath and/or fatigue and/or chest pain).
6. Unwilling or unable (per PhysIQ protocol) to wear telemonitoring patch.
7. Known clinically significant un-revascularized coronary artery disease, defined as: epicardial coronary artery stenosis with angina or other evidence of ongoing active coronary ischemia.
8. History of stroke, TIA, DVT, or pulmonary emboli within the past 6 months.
9. Known clinically significant untreated carotid artery stenosis likely to require intervention.
10. Presence of hemodynamically significant valve disease assessed by the site cardiologist and defined as: a. Mitral valve disease defined as grade $\geq 3+$ MR or > mild MS; OR b. Tricuspid valve regurgitation defined as grade $\geq 2+$ TR; OR c. Aortic valve disease defined as $\geq 2+$ AR or > moderate AS.
11. Hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis or other infiltrative cardiomyopathy (e.g. hemochromatosis, sarcoidosis)
12. Patient is contraindicated to receive either dual antiplatelet therapy, or an oral anticoagulant; or has a documented coagulopathy
13. Atrial fibrillation with resting HR > 100 BPM
14. Resting arterial oxygen saturation < 95% on room air
15. Significant hepatic impairment defined as 3X upper limit of normal of transaminases, total bilirubin, or alkaline phosphatase
16. Right ventricular dysfunction, assessed by the site cardiologist and defined as

a. More than mild RV dysfunction as estimated by TTE; OR
b. TAPSE < 1.4 cm; OR
c. RV size $\geq$ LV size as estimated by TTE; OR
d. Ultrasound or clinical evidence of congestive hepatopathy; OR
e. Evidence of RV dysfunction defined by TTE as an RV fractional area change < 35%;
17. Resting RAP > 14 mmHg
18. Evidence of significant pulmonary hypertension defined as PVR > 3.5 Woods units at rest or at peak exercise
19. Chronic pulmonary disease requiring continuous home oxygen, OR significant chronic pulmonary disease defined as FEV1 < 1L
20. Hemoglobin <10 g/dl
21. Currently participating in an investigational drug or device study that would interfere with the conduct or results of this study. Note: trials requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational
22. Life expectancy less than 12 months for known non-cardiovascular reasons
23. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation
24. Known or suspected allergy to nickel
25. Women of child bearing potential
26. Currently requiring dialysis; or estimated-GFR <25ml/min/1.73 m ² by CKD-Epi equation
27. Systolic blood pressure >170 mm Hg at screening
28. Patients with existing or surgically closed (with a patch) atrial septal defects. Patients with a PFO, who meet PCWP criteria despite the PFO, are not excluded.
29. Patients on significant immunosuppressive treatment or on systemic steroid treatment (>10 mg prednisone/day).

30. Severe obstructive sleep apnea not treated with CPAP or other measures
31. Severe depression and/or anxiety
32. In the opinion of the investigator, the patient is not an appropriate candidate for the study
33. Body mass index $>40 \text{ kg/m}^2$

Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; AR, aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; BMI, body mass index; BNP, brain natriuretic peptide; BPM, beats per minute; CABG, coronary artery bypass graft; CPAP, continuous positive airway pressure; DVT, deep vein thrombosis; EC, ethics committee; EF, ejection fraction; ESC, European Society of Cardiology; FEV1, forced expiratory volume in 1 second; GDMT, guideline directed medical therapy; GFR, glomerular filtration rate; HF, heart failure; HR, heart rate; IRB, institutional review board; IV, intravenous; LA, left atrium; LV, left ventricle; MI, myocardial infarction; MR, mitral regurgitation; MS, mitral stenosis; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; PFO, patent foramen ovale; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TAVR, transcatheter aortic valve replacement; TIA, transient ischemic attack; TR, tricuspid regurgitation; TTE, transthoracic echocardiography

TABLE 2: Secondary Outcome Measures REDUCE LAP-HF II Trial

Safety Related Outcome Measures
1. Device and or procedure related serious adverse cardiac events through 12 months
2. New onset or worsening of kidney dysfunction (defined as eGFR decrease of $> 20 \text{ ml/min/1.73 m}^2$) through 12 months
3. Cardiovascular mortality through 12 months
4. Cardiovascular mortality or non-fatal, ischemic stroke through 12 months
5. Major adverse cardiac events through 12 months defined as: a. Cardiac death b. Myocardial infarction c. Cardiac tamponade d. Emergency cardiac surgery
6. All serious adverse events through 12 months
7. All-cause mortality, and heart failure related mortality through 12 months
8. Newly acquired persistent or permanent atrial fibrillation or atrial flutter through 12 months
9. Implant embolization and clinically significant device migration through 12 months
10. Systemic embolic events through 12 months
11. Increase in RV size/decrease in RV function through 12 months
12. The need for implant removal or occlusion of the implant through 12 months
Efficacy Related Outcome Measures
1. Change in EQ-5D between baseline and 6 & 12 months
2. Change in NYHA class between baseline and 3, 6 & 12 months, as assessed by a blinded physician
3. Change in KCCQ between baseline and 3, 6 & 12 months
4. Change in 6MWT distance between baseline and 3, 6 & 12 months

5. Rate of total (first plus recurrent) HF admissions, healthcare facility visits for IV diuresis for HF through 12 months
6. Number of heart failure related hospitalization days and number of all ICU days through 12 months
7. Treatment for outpatient worsening of heart failure through 12 months
8. Days alive, and days not-hospitalized through 12 months
9. Change in blinded Investigator assessed NYHA classification between baseline and 3, 6 & 12 months
10. Echocardiographic assessment of shunt flow at 6 & 12 months
11. Change in BNP and/or NT-pro-BNP, and MR-ANP between baseline and 12 months
12. Changes in LA, LV dimensions, volume, and function, between baseline and 6 & 12 months assessed by an independent echocardiographic core laboratory
13. Changes in RA, LA, LV and RV dimensions, volume, and function between baseline and 6 & 12 months assessed by a cardiac MRI core laboratory (Sub-study only)
14. Change in CPET parameters (including exercise time) between baseline and 6 & 12 months as assessed by an independent blinded CPET core laboratory (Sub-study only)
15. Change in diuretic medications between baseline and 6 & 12 months
16. Healthcare cost through 2 years based on Health Economic data
17. Changes in the following telemonitoring parameters between baseline and 3, 6 & 12 months: a. Activity level b. Orthopnea incidence c. Arrhythmia incidence

6MWT, 6-minute walk test; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; CPET, cardiopulmonary exercise test; EQ-5D, EuroQol Five Dimensions Questionnaire; HF, heart failure; ICU, intensive care unit; KCCQ, Kansas City Cardiomyopathy Questionnaire; LA, left atrium; LV, left ventricle; MAR-ANP, midregional atrial natriuretic peptide; MRI, magnetic resonance imaging; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RA, right atrium; RV, right ventricle

Figure 1: The Corvia InterAtrial Shunt Device

Journal Pre-proof


Figure 2: Study Design

Journal Pre-proof



Figure 1

MULTICENTER, PROSPECTIVE, 1:1 RANDOMIZED, SHAM CONTROLLED, DOUBLE
BLINDED TRIAL



ENDPOINTS

The Primary endpoint is a composite of:

- Cardiovascular mortality or non-fatal, ischemic stroke through 12 months; and
- Rate of total (first plus recurrent) HF admissions, healthcare facility visits for IV diuresis for HF through 12 months; and
- Change in KCCQ score between baseline and 12 months.

Major secondary efficacy endpoints:

- Change in NYHA class between baseline and 12 months
- Change in KCCQ score between baseline and 12 months

The Primary endpoint will be analyzed using the Finkelstein-Schoenfeld methodology